Report of a meeting with 16 leading European experts in the field of diabetes & CVD discussing the role of novel diabetes drugs in the management of CVD
Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.
Three cardiology and diabetes experts speculate on how GLP-1 RAs and SGLT2 inhibitors may be benefitted from to lower CV risk, beyond treatment of T2DM patients. Also; may they be used simultaneously?
Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.
Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.
Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management of these patients.